Cortex Pharm Inc (CORX) 0.0750 $CORX
Cortex Pharmaceuticals, Inc. Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression, as well as obstructive, central and mixed sleep apnea, announces that effective September 18, 2014, the Company has entered into an agreement with the National Institute of Drug Abuse valued at $148,583 and entitled "Novel Treatment of Drug-Induced Respiratory Depression." The funding is a Phase 1 award granted under the Small Business Innovation Research Funding Award Program. The purpose of this project is to determine the most useful injectable route of administration for CX1942, the Company's proprietary, soluble ampakine, a potential rescue medication for drug-induced respiratory depression and lethality. Under the terms of the funded program, preclinical studies will be performed in collaboration with Dr. David Fuller, of the University of Florida, and Dr. John Greer, of the University of Alberta.
Cortex Pharmaceuticals, Inc. to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 5:00PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly drug-induced respiratory depression as well as obstructive, central and mixed sleep apneas, announces that it will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference (www.rodm.com). The conference will be held September 8 - 10, 2014 at the New York Palace Hotel sponsored by H.C. Wainwright & Co., LLC. The Company's Executive Chairman and CEO, Arnold S. Lippa, Ph.D., is currently scheduled to present at 3:45pm EDT on Wednesday, September 10, 2014.
Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members
GlobeNewswire - Thu Sep 04, 4:29PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression as well as obstructive, central and mixed sleep apnea, announces that James E. Sapirstein and Kathryn MacFarlane have joined the Board of Directors of the Company as independent directors. Both have distinguished careers in the biopharmaceutical industry and bring a depth and variety of professional experiences to the Cortex Board of Directors.
Cortex Pharmaceuticals, Inc. Enters Into New License Agreement With the University of Illinois Granting Cortex Patent Rights to the Use of Cannabinoids for the Treatment of Sleep Related Breathing Disorders
GlobeNewswire - Tue Jul 01, 4:30AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a biopharmaceutical company currently engaged in the development of drugs for respiratory disorders, announced today that it has entered into a new license agreement with the University of Illinois that provides Cortex with exclusive rights to patents claiming the use of cannabinoids for the treatment of sleep related breathing disorders. Cortex is developing dronabinol (D9-tetrahydrocannabinol), a cannabinoid, for the treatment of obstructive sleep apnea (OSA), the most common form of sleep apnea.
Fragile X Syndrome - Pipeline Review, H2 2013
M2 - Thu Jan 23, 8:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/gmtj7c/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2013" report to their offering. 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Scope - A snapshot of the global therapeutic scenario for Fragile X Syndrome. - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned F. Hoffmann-La Roche Ltd. Novartis AG Paratek Pharmaceuticals, Inc. Neuren Pharmaceuticals Limited Cortex Pharmaceuticals, Inc. Seaside Therapeutics, LLC Snowdon Inc. Marinus Pharmaceuticals, Inc. Nexgenix Pharmaceuticals, LLC aFraxis Inc. Alcobra Ltd Sage Therapeutics Confluence Pharmaceuticals LLC SMaRT Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/gmtj7c/fragile_x About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Huntingtons Disease Therapeutics - 2013 Global Strategic Business Report
M2 - Fri Aug 02, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnkpxr/huntingtons#summary) has announced the addition of the "Huntingtons Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntingtons Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Hd Therapeutics Market Trends 3. Hd Research And Drug Pipeline 4. Research Breakthroughs In Hd Arena 5. An Overview Of Huntington's Disease 6. Clinical Trials 7. Recent Industry Activity 8. Corporate Activity In The Recent Past - A Perspective Builder 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Europe 3. Rest Of World IV. Competitive Landscape Companies Mentioned The report profiles 35 companies including - Alnylam Pharmaceuticals - AmpliPhi Biosciences Corp. - Ceregene - Cortex Pharmaceuticals - Intellect Neurosciences Incorporation - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - Teva Pharmaceutical Industries Ltd. - Trophos SA - Valeant Pharmaceuticals International - Vertex Pharmaceuticals Incorporated. For more information, including full list of companies profiled, please visit http://www.researchandmarkets.com/research/tn...ns#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Respiratory Depression - Pipeline Review, H2 2012
M2 - Wed Jul 31, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2jm9kb/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Respiratory Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Depression. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Respiratory Depression. - A review of the Respiratory Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Respiratory Depression. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Respiratory Depression pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Respiratory Depression Overview Therapeutics Development An Overview of Pipeline Products for Respiratory Depression Companies Involved in Respiratory Depression Therapeutics Development Respiratory Depression - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Cortex Pharmaceuticals - Galleon Pharmaceuticals - Sihuan Pharmaceutical Holdings Group Ltd For more information visit http://www.researchandmarkets.com/research/2j...espiratory
Sleep Apnea - Pipeline Review, H1 2013
M2 - Mon Jun 17, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6fqjfg/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H1 2013" report to their offering. 'Sleep Apnea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for sleep apnea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for sleep apnea. Scope - A snapshot of the global therapeutic scenario for Sleep Apnea. - A review of the Sleep Apnea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sl
Huntington's Disease - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:33AM CDT
Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering. 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indicatio
Fragile X Syndrome - Pipeline Review, H2 2012 Report Reviews Key Players Involved In the Therapeutic Development for Fragile X Syndrome
M2 - Mon Dec 17, 9:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/rck2wt/fragile_x) has announced the addition of Global Markets Direct's new report "Fragile X Syndrome - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Fragile X Syndrome - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Fragile X Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global thera
Cortex Pharmaceuticals, Inc. Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression, as well as obstructive, central and mixed sleep apnea, announces that effective September 18, 2014, the Company has entered into an agreement with the National Institute of Drug Abuse valued at $148,583 and entitled "Novel Treatment of Drug-Induced Respiratory Depression." The funding is a Phase 1 award granted under the Small Business Innovation Research Funding Award Program. The purpose of this project is to determine the most useful injectable route of administration for CX1942, the Company's proprietary, soluble ampakine, a potential rescue medication for drug-induced respiratory depression and lethality. Under the terms of the funded program, preclinical studies will be performed in collaboration with Dr. David Fuller, of the University of Florida, and Dr. John Greer, of the University of Alberta. Cortex Pharmaceuticals, Inc. to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 5:00PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly drug-induced respiratory depression as well as obstructive, central and mixed sleep apneas, announces that it will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference (www.rodm.com). The conference will be held September 8 - 10, 2014 at the New York Palace Hotel sponsored by H.C. Wainwright & Co., LLC. The Company's Executive Chairman and CEO, Arnold S. Lippa, Ph.D., is currently scheduled to present at 3:45pm EDT on Wednesday, September 10, 2014. Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members
GlobeNewswire - Thu Sep 04, 4:29PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression as well as obstructive, central and mixed sleep apnea, announces that James E. Sapirstein and Kathryn MacFarlane have joined the Board of Directors of the Company as independent directors. Both have distinguished careers in the biopharmaceutical industry and bring a depth and variety of professional experiences to the Cortex Board of Directors. Cortex Pharmaceuticals, Inc. Enters Into New License Agreement With the University of Illinois Granting Cortex Patent Rights to the Use of Cannabinoids for the Treatment of Sleep Related Breathing Disorders
GlobeNewswire - Tue Jul 01, 4:30AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a biopharmaceutical company currently engaged in the development of drugs for respiratory disorders, announced today that it has entered into a new license agreement with the University of Illinois that provides Cortex with exclusive rights to patents claiming the use of cannabinoids for the treatment of sleep related breathing disorders. Cortex is developing dronabinol (D9-tetrahydrocannabinol), a cannabinoid, for the treatment of obstructive sleep apnea (OSA), the most common form of sleep apnea. Fragile X Syndrome - Pipeline Review, H2 2013
M2 - Thu Jan 23, 8:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/gmtj7c/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2013" report to their offering. 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Scope - A snapshot of the global therapeutic scenario for Fragile X Syndrome. - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned F. Hoffmann-La Roche Ltd. Novartis AG Paratek Pharmaceuticals, Inc. Neuren Pharmaceuticals Limited Cortex Pharmaceuticals, Inc. Seaside Therapeutics, LLC Snowdon Inc. Marinus Pharmaceuticals, Inc. Nexgenix Pharmaceuticals, LLC aFraxis Inc. Alcobra Ltd Sage Therapeutics Confluence Pharmaceuticals LLC SMaRT Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/gmtj7c/fragile_x About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Huntingtons Disease Therapeutics - 2013 Global Strategic Business Report
M2 - Fri Aug 02, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnkpxr/huntingtons#summary) has announced the addition of the "Huntingtons Disease Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Huntingtons Disease Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Hd Therapeutics Market Trends 3. Hd Research And Drug Pipeline 4. Research Breakthroughs In Hd Arena 5. An Overview Of Huntington's Disease 6. Clinical Trials 7. Recent Industry Activity 8. Corporate Activity In The Recent Past - A Perspective Builder 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Europe 3. Rest Of World IV. Competitive Landscape Companies Mentioned The report profiles 35 companies including - Alnylam Pharmaceuticals - AmpliPhi Biosciences Corp. - Ceregene - Cortex Pharmaceuticals - Intellect Neurosciences Incorporation - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - Teva Pharmaceutical Industries Ltd. - Trophos SA - Valeant Pharmaceuticals International - Vertex Pharmaceuticals Incorporated. For more information, including full list of companies profiled, please visit http://www.researchandmarkets.com/research/tn...ns#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Respiratory Depression - Pipeline Review, H2 2012
M2 - Wed Jul 31, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2jm9kb/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Respiratory Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Depression. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Respiratory Depression. - A review of the Respiratory Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Respiratory Depression. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Respiratory Depression pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Respiratory Depression Overview Therapeutics Development An Overview of Pipeline Products for Respiratory Depression Companies Involved in Respiratory Depression Therapeutics Development Respiratory Depression - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Cortex Pharmaceuticals - Galleon Pharmaceuticals - Sihuan Pharmaceutical Holdings Group Ltd For more information visit http://www.researchandmarkets.com/research/2j...espiratory
Sleep Apnea - Pipeline Review, H1 2013
M2 - Mon Jun 17, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6fqjfg/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H1 2013" report to their offering. 'Sleep Apnea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for sleep apnea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for sleep apnea. Scope - A snapshot of the global therapeutic scenario for Sleep Apnea. - A review of the Sleep Apnea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sl
Huntington's Disease - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:33AM CDT
Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering. 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indicatio
Fragile X Syndrome - Pipeline Review, H2 2012 Report Reviews Key Players Involved In the Therapeutic Development for Fragile X Syndrome
M2 - Mon Dec 17, 9:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/rck2wt/fragile_x) has announced the addition of Global Markets Direct's new report "Fragile X Syndrome - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Fragile X Syndrome - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Fragile X Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global thera
